{"trials":[{"id":3529,"nct_id":"NCT06299319","title":"Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06299319","tracker_url":"publication.php?id=3529","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-03","last_update_date":"2026-09-24","start_date":"2024-09-01","primary_completion_date":"2026-09-04","completion_date":"2026-09-04","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3651,"nct_id":"NCT05546658","title":"Effects of Psilocybin in Obsessive Compulsive Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05546658","tracker_url":"publication.php?id=3651","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2022-11-28","primary_completion_date":"2026-12-30","completion_date":"2027-09-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":35,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3710,"nct_id":"NCT07347405","title":"A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","sponsor":"Francisco A Moreno","registry_url":"https://clinicaltrials.gov/study/NCT07347405","tracker_url":"publication.php?id=3710","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-07-23","start_date":"2026-05-18","primary_completion_date":"2028-12-31","completion_date":"2029-01-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin 10 mg","type":"DRUG"},{"name":"Psilocybin 20 mg","type":"DRUG"},{"name":"Psilocybin 30 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648}],"countries":["United States"]},{"id":3664,"nct_id":"NCT05370911","title":"Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT05370911","tracker_url":"publication.php?id=3664","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-04","start_date":"2023-07-20","primary_completion_date":"2026-02-17","completion_date":"2027-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":28,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"4662514f893f3efe4da6f3a3a4ba0f9edfcd2d0e99897470f8dae3ff6d2f70fd","facility":"Enact Research Collaborative (40 Temple St, 4th Floor)","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"6c4e35a8a1d85d417c6c566904ebcd1766b91b815d9762c5e984afa8b2885908","facility":"Yale Program for Psychedelic Research","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3488,"nct_id":"NCT03356483","title":"Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT03356483","tracker_url":"publication.php?id=3488","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-20","start_date":"2018-11-13","primary_completion_date":"2024-07-25","completion_date":"2024-07-25","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":31,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin (0.25mg/kg)","type":"DRUG"},{"name":"Niacin (250mg)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3669,"nct_id":"NCT06258031","title":"PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06258031","tracker_url":"publication.php?id=3669","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-06","start_date":"2022-10-28","primary_completion_date":"2024-06-28","completion_date":"2024-07-24","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":19,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin (COMP360)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2018":1,"2022":2,"2023":1,"2024":1,"2026":1},"statuses":{"Completed":3,"Active, not recruiting":2,"Recruiting":1},"conditions":{"Obsessive-Compulsive Disorder":6},"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648},{"key":"4662514f893f3efe4da6f3a3a4ba0f9edfcd2d0e99897470f8dae3ff6d2f70fd","facility":"Enact Research Collaborative (40 Temple St, 4th Floor)","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"6c4e35a8a1d85d417c6c566904ebcd1766b91b815d9762c5e984afa8b2885908","facility":"Yale Program for Psychedelic Research","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"enrollment":{"sum":153,"known_trials":6},"registry_checked_at_utc":"2026-10-09 01:24:43"}